Healthcare veterans from biopharma industry, agency and advisory firms will deliver tech-enabled insight, influence and action NEW YORK–(BUSINESS WIRE)–Real ChemistryHealthcare veterans from biopharma industry, agency and advisory firms will deliver tech-enabled insight, influence and action NEW YORK–(BUSINESS WIRE)–Real Chemistry

Real Chemistry Establishes RC Resolve, an Advisory Practice for Healthcare’s Most Critical Business, Regulatory and Value Inflection Points

Healthcare veterans from biopharma industry, agency and advisory firms will deliver tech-enabled insight, influence and action

NEW YORK–(BUSINESS WIRE)–Real Chemistry today announced the launch of RC Resolve, a healthcare advisory practice designed to help leaders navigate the value inflection points where science, business, economics, policy and risk management intersect. RC Resolve offers a new end-to-end model of healthcare advisory informed by deep expertise and real-time insights to deliver communication strategies and execution that drive desired outcomes.

“The healthcare industry is at a critical juncture, with the pace, complexity and consequences of decision-making accelerating rapidly,” said Jennifer Gottlieb, Global President and Head of Integrated Communications at Real Chemistry. “Healthcare leaders today are seeking highly specialized partners that combine deep industry expertise with advisory capabilities to navigate the regulatory shifts, reputational risk and financial uncertainties of the operating environment that make advancing business and science more complicated, more risky and potentially more costly. RC Resolve was created to meet this need, building on Real Chemistry’s 25-year legacy as a leading data-driven healthcare partner – bringing together seasoned industry leaders who have walked in our clients’ shoes and have decades of experience to help organizations move forward with clarity, confidence and decisive action.”

RC Resolve leverages proprietary, AI-powered intelligence, including ReputAI, an advanced reputation measurement and predictive message-testing suite, and HealthGEO, which assesses how large language models influence corporate perception to drive message clarity and measurable impact. Backed by Real Chemistry’s 2,000+ experts across life sciences, marketing communications and technology, RC Resolve provides healthcare advisory counsel – combining deep sector perspective with strategic foresight – to help organizations navigate complexity, strengthen trust and stay ahead of change.

RC Resolve’s advisory practice spans critical areas that meet clients’ most pressing communication needs, including:

  • Policy, Public Affairs and Access
  • Issues, Crisis and Risk Management
  • Transformation and Change Management
  • Executive Communications
  • Corporate Strategy and Reputation
  • Financial and Transaction Communications

RC Resolve’s Seasoned Senior A-Team

“RC Resolve was built specifically to bring together senior health advisors who understand the pressures from the outside in and can help leaders make confident, enterprise-level decisions with speed and precision – when it matters most,” said Sherry Pudloski, Group President of RC Resolve and Corporate Affairs at Real Chemistry. Pudloski previously served as chief communications and corporate affairs officer at Seagen, Zoetis and Guardian Life and held senior communications and strategy roles at Pfizer and Novartis.

RC Resolve comprises veterans with more than 20 years of experience advising leaders in the boardroom, newsroom, crisis room and policy environment, including:

  • Bridget Walsh, Head of Policy, Public Affairs and Access, held government affairs and policy leadership roles at Pfizer and Boehringer Ingelheim, including 10 years on Capitol Hill as a senior staffer to U.S. Senators.
  • Margaret (Maggie) Farley, Head of Issues, Crisis and Risk Management, is a renowned counselor across biopharmaceutical and medical device communications who led health crises and issues management at Edelman for two decades.
  • Amy Atwood, Head of Transformation and Change Management, brings deep experience leading corporate communications, change management and strategic transformation across global healthcare enterprises, most recently as Vice President, U.S. and Global Corporate Communications at Takeda.
  • Shoreen Maghame, Head of Executive Communications, is a strategic communications advisor to C-suite executives on global launches, crises and reputation management whose early career experience as an on-air journalist informs her practical, media-savvy approach to executive communications.
  • Piper Evans, Head of Corporate Strategy and Reputation, advises executives across academic medicine, integrated delivery systems, emerging biotechs and global health organizations. She joins from FGS Global and previously held positions at McKinsey & Company, Purple Strategies and the Public Affairs Council.
  • Leslie Isenegger, Head of Client Development, has industry-leading policy and pricing expertise and was most recently head of Real Chemistry’s Corporate Pricing and Public Affairs practice. She previously held positions at the Centers for Medicare & Medicaid Services (CMS) and the Greater New York Hospital Association.

RC Resolve’s Healthcare Advisory Council

Backing up the RC Resolve A-Team is a Healthcare Advisory Council of senior leaders with deep experience across regulatory, legal, health economics, healthcare financing and corporate affairs who will provide enterprise-level perspective and strategic decision-making.

Current members include Jim Weiss, Founder and Chairman of Real Chemistry; Shankar Narayanan, Chief Executive Officer (CEO) at Real Chemistry and former Partner, McKinsey & Company; Kirsten Axelsen, health economics expert and Senior Policy Advisor at DLA Piper; Murphy Gallagher, Senior Managing Director at Leerink Partners; Erica Jefferson, former Associate Commissioner for External Affairs at the U.S. Food and Drug Administration (FDA); and Alan Minsk, Partner and Co-Chair of the Food and Drug Practice team at Arnall Golden Gregory LLP. The membership of RC Resolve’s Healthcare Advisory Council will evolve alongside the healthcare and policy landscape, ensuring access to relevant expertise as novel issues and opportunities emerge.

“As a privately held company focused exclusively on healthcare, we’ve stayed true to our commitment to invest where it matters most for our clients’ growth,” said Narayanan. “Building on our strong momentum in 2025 – including expansion of our omni-first precision marketing and media group – RC Resolve is one of several new offerings we’re bringing to market in 2026, along with continued advances in AI-driven intelligence and delivery and our expanding global footprint.”

About RC Resolve

RC Resolve is Real Chemistry’s advisory practice for healthcare’s most critical business, regulatory and value inflection points where science, business, economics, policy and risk management intersect. RC Resolve combines insight, influence and decisive action to help organizations achieve desired outcomes and emerge stronger, more trusted and better prepared for what’s next.

About Real Chemistry: 25 Years of Future-Focused Healthcare

Celebrating its 25th anniversary this year, Real Chemistry is a tier-one partner to the world’s most innovative life sciences and healthcare companies. As a leading provider of AI-powered audience analytics and insights, Real Chemistry helps the healthcare industry better understand, reach and engage critical audiences to improve the healthcare experience for all. Anchored by our culture of innovation and creativity, Real Chemistry’s 2,000+ global experts across life sciences, marketing communications and technology are singularly focused on navigating the complexities of bringing scientific advances to market and, most importantly, to the people who need them. Learn more at www.realchemistry.com.

Contacts

Media Contact:

media@realchemistry.com

Market Opportunity
RealLink Logo
RealLink Price(REAL)
$0.07528
$0.07528$0.07528
-1.34%
USD
RealLink (REAL) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Gold Hits $3,700 as Sprott’s Wong Says Dollar’s Store-of-Value Crown May Slip

Gold Hits $3,700 as Sprott’s Wong Says Dollar’s Store-of-Value Crown May Slip

The post Gold Hits $3,700 as Sprott’s Wong Says Dollar’s Store-of-Value Crown May Slip appeared on BitcoinEthereumNews.com. Gold is strutting its way into record territory, smashing through $3,700 an ounce Wednesday morning, as Sprott Asset Management strategist Paul Wong says the yellow metal may finally snatch the dollar’s most coveted role: store of value. Wong Warns: Fiscal Dominance Puts U.S. Dollar on Notice, Gold on Top Gold prices eased slightly to $3,678.9 […] Source: https://news.bitcoin.com/gold-hits-3700-as-sprotts-wong-says-dollars-store-of-value-crown-may-slip/
Share
BitcoinEthereumNews2025/09/18 00:33
Oklo Stock: Meta’s Nuclear Power Play Triggers 20% Rally

Oklo Stock: Meta’s Nuclear Power Play Triggers 20% Rally

TLDR Oklo stock surged 20% after Meta deal for 1.2 gigawatt nuclear power campus in Pike County, Ohio Meta prepays for power and funds Oklo’s Aurora powerhouse
Share
Coincentral2026/01/10 15:02
Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC

Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC

The post Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC appeared on BitcoinEthereumNews.com. Franklin Templeton CEO Jenny Johnson has weighed in on whether the Federal Reserve should make a 25 basis points (bps) Fed rate cut or 50 bps cut. This comes ahead of the Fed decision today at today’s FOMC meeting, with the market pricing in a 25 bps cut. Bitcoin and the broader crypto market are currently trading flat ahead of the rate cut decision. Franklin Templeton CEO Weighs In On Potential FOMC Decision In a CNBC interview, Jenny Johnson said that she expects the Fed to make a 25 bps cut today instead of a 50 bps cut. She acknowledged the jobs data, which suggested that the labor market is weakening. However, she noted that this data is backward-looking, indicating that it doesn’t show the current state of the economy. She alluded to the wage growth, which she remarked is an indication of a robust labor market. She added that retail sales are up and that consumers are still spending, despite inflation being sticky at 3%, which makes a case for why the FOMC should opt against a 50-basis-point Fed rate cut. In line with this, the Franklin Templeton CEO said that she would go with a 25 bps rate cut if she were Jerome Powell. She remarked that the Fed still has the October and December FOMC meetings to make further cuts if the incoming data warrants it. Johnson also asserted that the data show a robust economy. However, she noted that there can’t be an argument for no Fed rate cut since Powell already signaled at Jackson Hole that they were likely to lower interest rates at this meeting due to concerns over a weakening labor market. Notably, her comment comes as experts argue for both sides on why the Fed should make a 25 bps cut or…
Share
BitcoinEthereumNews2025/09/18 00:36